You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Comprehensive Glycoproteomic Tool Development for Cancer Biomarkers

    SBC: Protein Metrics Inc.            Topic: 400

    Project SummaryGlycosylation is one of the most prevalent and important post translational modifications of proteinsyet it is also one of the most difficult to studyNo single method nor analytical platform can give complete information about the glycosylation in a protein sampleand the analytical methods in current use include both ESI and MALDI single and tandem mass spectrometryat least four typ ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Augmenting Dual Energy CT for Novel Contrast Agents

    SBC: NEXTRAST, INC            Topic: 300

    Project SummaryAbstract Our long term goal is to revolutionize the effectiveness of CT imaging for millions of Americans across a broad range of abdominal diseaseDual energy CTDECTprovides powerful clinical diagnostic potential but remains heavily underutilized despite wide scanner availabilityDECT allows materials to be differentiated based on their relative X ray attenuation at low versus high e ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    ABSTRACTTechnology to deliveron demandmolecules that bind targets or catalyze reactions of choice has been a goal of chemistry foryearsEven todaytheory is inadequate to support de novo design of receptors having useful affinity or catalysts having useful turnoverThusmany have sought to create those catalysts on a DNA or RNAcollectivelyxNAusing the Darwinism to these biomolecules to evolveunder lab ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a novel therapy for diabetic retinopathy

    SBC: Everglades Biopharma, LLC            Topic: W

    Project Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Automated Electrophysiology Assessment of Drug induced Cardiotoxicity Based on Parallel Noninvasive Nanoelectrode Array

    SBC: CYION TECHNOLOGIES LLC            Topic: NIBIB

    Summary Drug safety issues pose a serious challenge to the health and well being of patients The development of our innovative technology aims to address a significant gap in the in vitro assessment of drug induced cardiotoxicity which is the number one reason for withdrawals of all marketed drugs as well as the premature termination of promising drug development candidates Pressured by the eno ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD Biotherapeutics Inc.            Topic: NIDDK

    DESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Skin Microbiome Editing with Fermentation Initiator

    SBC: Surface Bioadvances, Inc.            Topic: NIAMS

    Abstract Acne dysbiosis is defined as microbial imbalance with the over growth of Propionibacterium acnes P acnes in the acne microbiome We have demonstrated that Staphylococcus epidermidis S epidermidis a probiotic bacterium co existed with P acnes in an acne lesion can exploit the carbohydrate fermentation to produce short chain fatty acids SCFAs and rein in the over growth of P ac ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Probabilistic Modeling for Software Guided Radiotherapy Patient Plan QA

    SBC: SUN NUCLEAR CORP.            Topic: 103

    Errors in the planning and delivery of radiation therapy can result in inferior outcomes for patients The magnitude of this problem is now well appreciated from cooperative group trials and other sources At present however there are few concrete tools to reduce the chance of plan errors passing undetected Current practice uses a variety of error mitigation means such as human inspection of th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government